1. Supernus Closes $350 Million Deal for Navitor's SPN-820, Betting Big on New Asset
Supernus Pharmaceuticals has finalized a major $350 million asset acquisition, securing full rights to Navitor Pharmaceuticals' SPN-820. This high-value transaction immediately transfers all development and commercialization responsibilities for the investigational compound to Supernus, marking a significant strategic ...